Cardiology - Global Cardiology Academy

81-96 of 334

Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
On the Frontlines of ATTR-CM
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
Steve Jackson, PharmD; Karola Jering, MD
- Steve Jackson, PharmD
- Karola Jering, MD
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CM
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
Shelina Ramnarine, PhD; Chadi Alraies, MD, MPH, FACC
- Shelina Ramnarine, PhD
- Chadi Alraies, MD, MPH, FACC
Tracking Disease Progression in ATTR-CM
Tracking Disease Progression in ATTR-CM
On the Frontlines of ATTR-CM
Tracking Disease Progression in ATTR-CM
Ryan Quigley; Joban Vaishnav, MD
- Ryan Quigley
- Joban Vaishnav, MD
Can AI Transform How We Diagnose ATTR-CM?
Can AI Transform How We Diagnose ATTR-CM?
On the Frontlines of ATTR-CM
Can AI Transform How We Diagnose ATTR-CM?
Ryan Quigley; Frederick Ruberg, MD
- Ryan Quigley
- Frederick Ruberg, MD
MinuteCE®
The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
Javed Butler, MD; Prof. Dr. Johann Bauersachs
0.75 credits 5 episodes
- Javed Butler, MD
- Prof. Dr. Johann Bauersachs
- Carolyn Lam, MD, PhD
0.75 credits 5 episodes
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
MinuteCE®
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
Javed Butler, MD; Carolyn Lam, MD, PhD
0.75 program credits
- Javed Butler, MD
- Carolyn Lam, MD, PhD
0.75 program credits
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
CME/CE
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
Prof. Dr. Johann Bauersachs; Carolyn Lam, MD, PhD
0.25 credits
- Prof. Dr. Johann Bauersachs
- Carolyn Lam, MD, PhD
0.25 credits
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Ashkan Shoamanesh, MD
- Ashkan Shoamanesh, MD
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Mike Sharma, MD, MSc, FRCPC
- Mike Sharma, MD, MSc, FRCPC
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
On the Frontlines of ATTR-CM
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
Ryan Quigley; Ahmad Masri, MD, MS
- Ryan Quigley
- Ahmad Masri, MD, MS
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
CME/CE
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
Stephen J. Greene, MD; Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
- Stephen J. Greene, MD
- Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart Matters
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Ahmad Masri, MD, MS
- Ahmad Masri, MD, MS
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
On the Frontlines of ATTR-CM
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
Ryan Quigley; Kevin Alexander, MD
- Ryan Quigley
- Kevin Alexander, MD
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart Matters
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Kevin Alexander
- Kevin Alexander
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Richard E. Pratley, MD; David Cherney, MD, PhD
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
On the Frontlines of ATTR-CM
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Ryan Quigley; Quan Bui, MD
- Ryan Quigley
- Quan Bui, MD

Previous
1
2
…
4
5
6
7
8
…
20
21
Next

6/11